celecoxib has been researched along with Orthopedic Disorders in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment-emergent hepatobiliary adverse events (AEs) were compared for celecoxib <200 mg/day (943 patients), 200 mg/day (12 008 patients), 400 mg/day (7380 patients), and 800 mg/day (4602 patients); placebo (4057 patients); diclofenac 100-150 mg/day (7639 patients); naproxen 1000 mg/day (2953 patients); and ibuprofen 2400 mg/day (2484 patients)." | 2.45 | The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. ( Cawkwell, G; Li, C; Ma, H; Shell, B; Soni, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soni, P | 1 |
| Shell, B | 1 |
| Cawkwell, G | 1 |
| Li, C | 1 |
| Ma, H | 1 |
| Rahme, E | 1 |
| Toubouti, Y | 1 |
| Hunsche, E | 1 |
1 review available for celecoxib and Orthopedic Disorders
| Article | Year |
|---|---|
The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Drug Tolerance; Female; | 2009 |
1 other study available for celecoxib and Orthopedic Disorders
| Article | Year |
|---|---|
Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |